organization · Reporting owner
SALMON Pharma GmbH
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.VLON · Entity 8336 | 10% owner | February 12, 2021 | February 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date February 12, 2021 · Filed February 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,063 |
Reported balance
After 2021-02-12 transaction · row 1
1 source rowRow 1 · 2021-02-12 · Other · Acquired 47,063 · Balance 47,063 F1: Issued immediately prior to the closing of the initial public offering of the issuer's common stock in connection with the conversion of the promissory notes held by the reporting person, as disclosed in the prospectus, dated February 9, 2021, filed with the U.S. Securities and Exchange Commission on February 11, 2021, which forms a part of the Registration Statements on Form S-1 (File Nos. 333-249636 and 333-252925), originally filed on October 23, 2020, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued immediately prior to the closing of the initial public offering of the issuer's common stock in connection with the conversion of the promissory notes held by the reporting person, as disclosed in the prospectus, dated February 9, 2021, filed with the U.S. Securities and Exchange Commission on February 11, 2021, which forms a part of the Registration Statements on Form S-1 (File Nos. 333-249636 and 333-252925), originally filed on October 23, 2020, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 12, 2021 23:02 UTC | GRI Bio, Inc. VLON · Entity 8336 | OtherCommon Stock | 47,063 | $6.40 | $301,203.20 |
DisclosureSEC source: 0001104659-21-022188 · tm214979-10_4seq1.xml · nonDerivative · entry 1 SALMON Pharma GmbH · CIK 0001843677 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,063 F1 · kind: Issued immediately prior to the closing of the initial public offering of the issuer's common stock in connection with the conversion of the promissory notes held by the reporting person, as disclosed in the prospectus, dated February 9, 2021, filed with the U.S. Securities and Exchange Commission on February 11, 2021, which forms a part of the Registration Statements on Form S-1 (File Nos. 333-249636 and 333-252925), originally filed on October 23, 2020, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.